Table 2.

Treatment Characteristics

Characteristic	N (%)
Type of Systemic Therapy
Immunotherapy Alone	19 (56%)
Immunotherapy + Chemotherapy	16 (44%)
PD-1/PD-L1 Inhibitor
Pembrolizumab	33 (94%)
Nivolumab	1 (3%)
Atezolizumab	1 (3%)
Expected Probability of Response
Low (CPI alone, PD-L1 0–49%)	5 (15%)
Intermediate (CPI alone, PD-L1 50–100%)	14 (42%)
High (chemo-CPI, any PD-L1)	14 (42%)
Initial Irradiated Site
Peripheral Lung Primary	15 (44%)
Central Lung Primary/Hilum	8 (21%)
Lymph Node Metastasis	4 (12%)
Liver Metastasis	3 (9%)
Adrenal Metastasis	2 (6%)
Soft Tissue/Bone Metastasis	2 (6%)
Lung Metastasis	1 (3%)
Subsequent Course(s) of Radiation
Yes	15 (44%)
No	20 (56%)